Recent studies have mapped the genome in large AML cohorts and found mutations in more than 60% of AML patients that confer abnormal "carcinogenic" activation, such as the PI3K/AKT signaling pathway, particularly in high-risk groups of AML patients [30]. This evidence concerns the gene AKT1 and acute myeloid leukemia.